Aclaris Therapeutics (ACRS) Competitors $1.61 +0.02 (+1.26%) Closing price 04:00 PM EasternExtended Trading$1.56 -0.05 (-3.11%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPBShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals Upstream Bio Maravai LifeSciences (NASDAQ:MRVI) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Is MRVI or ACRS more profitable? Maravai LifeSciences has a net margin of -67.14% compared to Aclaris Therapeutics' net margin of -732.42%. Maravai LifeSciences' return on equity of -12.91% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-67.14% -12.91% -6.87% Aclaris Therapeutics -732.42%-30.73%-22.74% Which has more risk & volatility, MRVI or ACRS? Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Does the media favor MRVI or ACRS? In the previous week, Maravai LifeSciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 2 mentions for Maravai LifeSciences and 0 mentions for Aclaris Therapeutics. Maravai LifeSciences' average media sentiment score of 1.05 beat Aclaris Therapeutics' score of 0.68 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Overall Sentiment Maravai LifeSciences Positive Aclaris Therapeutics Positive Do insiders and institutionals have more ownership in MRVI or ACRS? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, MRVI or ACRS? Aclaris Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.18M2.39-$144.85M-$1.14-2.13Aclaris Therapeutics$18.72M9.31-$132.07M-$1.39-1.16 Do analysts rate MRVI or ACRS? Maravai LifeSciences presently has a consensus price target of $6.64, indicating a potential upside of 173.21%. Aclaris Therapeutics has a consensus price target of $8.71, indicating a potential upside of 441.26%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryAclaris Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.17M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-1.164.4521.0120.09Price / Sales9.31709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book1.125.008.125.65Net Income-$132.07M$30.99M$3.25B$257.91M7 Day Performance2.55%1.69%0.97%2.09%1 Month Performance13.38%9.20%7.36%11.13%1 Year Performance22.90%-1.25%31.31%18.40% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.2089 of 5 stars$1.61+1.3%$8.71+441.3%+20.5%$172.17M$18.72M-1.16100MRVIMaravai LifeSciences3.5373 of 5 stars$2.67-2.2%$6.64+148.6%-73.0%$679.94M$259.18M-2.34610Positive NewsIOVAIovance Biotherapeutics4.7457 of 5 stars$2.01+7.5%$12.22+508.1%-73.8%$671.20M$164.07M-1.62500Analyst DowngradeAnalyst RevisionGap UpHigh Trading VolumeURGNUrogen Pharma4.337 of 5 stars$14.49+1.8%$32.86+126.8%-8.8%$668.13M$90.40M-4.56200TLRYTilray Brands1.8639 of 5 stars$0.66+13.1%$1.92+191.8%-67.8%$661.07M$788.94M-0.632,650TNGXTango Therapeutics1.65 of 5 stars$6.09+2.7%$12.20+100.3%-29.7%$660.12M$40.99M-4.9990STOKStoke Therapeutics4.2311 of 5 stars$12.06+1.7%$24.75+105.2%-9.7%$658.48M$36.56M15.27100Analyst ForecastGap UpPRMEPrime Medicine3.8285 of 5 stars$4.80+10.3%$10.08+110.1%-38.0%$645.57M$3.85M-2.34234News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeDNTHDianthus Therapeutics1.1441 of 5 stars$20.03-0.1%$53.00+164.6%-26.5%$644.17M$6.24M-6.9580PHATPhathom Pharmaceuticals4.3042 of 5 stars$9.06-1.3%$17.50+93.2%-31.3%$632.48M$55.25M-1.73110UPBUpstream Bio1.7981 of 5 stars$11.73+2.2%$56.50+381.7%N/A$631.00M$2.30M0.0038 Related Companies and Tools Related Companies Maravai LifeSciences Competitors Iovance Biotherapeutics Competitors Urogen Pharma Competitors Tilray Brands Competitors Tango Therapeutics Competitors Stoke Therapeutics Competitors Prime Medicine Competitors Dianthus Therapeutics Competitors Phathom Pharmaceuticals Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
